Alnylam Hit Hard As Investors Forced To Revise Future Profit Expectations
Source: SeekingAlpha
2026-02-13 15:07:01 ET
It’s been a rough go for Alnylam Pharmaceuticals ( ALNY ) since October 2025, with the shares down almost 40% from an all-time high. While it is typically clinical failures that hit biotechs hard, Alnylam is in that awkward biopharma adolescence where investors care more and more about the actual financials. To that end, worries about dynamics in the core TTR market and future profitability loom larger than any concerns about the clinical pipeline....
Read the full article on Seeking Alpha
For further details see:
Alnylam Hit Hard As Investors Forced To Revise Future Profit Expectations
Sanofi
NASDAQ: SNY
SNY Trading
-0.77% G/L:
$43.65 Last:
933,628 Volume:
$43.90 Open:
SNY Latest News
February 23, 2026 01:42:29 pm
Kraig Biocraft Laboratories Featured on the Cover of National Geographic
February 18, 2026 08:45:56 am
It's Not Synthetic, It's Real. Kraig Labs Nears Spider Silk Breakthrough
SNY Stock Data
$119,804,457,217
2,430,957,423
N/A
389
N/A
Pharmaceuticals
Healthcare
FR
Paris
